More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.73B
EPS
-3.77
P/E ratio
--
Price to sales
57.86
Dividend yield
--
Beta
1.363206
Previous close
$26.63
Today's open
$26.66
Day's range
$26.16 - $27.14
52 week range
$22.05 - $40.22
show more
CEO
Ian F. Smith
Employees
170
Headquarters
Bedford, MA
Exchange
Nasdaq Global Select
Shares outstanding
65406268
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on November 16, 2026, it granted stock options to purchase an aggregate of 99,050 shares of common stock to ele.
Business Wire • 17 hours ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in November
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the following upcoming investo.
Business Wire • Nov 3, 2026

Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

Stoke Therapeutics Q3 Earnings Call Highlights
Stoke Therapeutics NASDAQ: STOK said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is advancing toward a planned third-quarter 2027 data readout, while the company prepares for a potential U.S. regulatory submission later that year and a possible launch in early 2028.
MarketBeat • Oct 30, 2026

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the third quarter ended September 30, 2026, and provided business updates including progress of the global.
Business Wire • Oct 29, 2026

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $0.65 per share a year ago.
Zacks Investment Research • Oct 30, 2026

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m.
Business Wire • Oct 22, 2026

Stoke Therapeutics: The Market Misread A Key FDA Win
Stoke Therapeutics is positioned for a pivotal 2027 readout of zorevunersen, potentially the first disease-modifying Dravet syndrome therapy. STOK's cash runway extends to early 2028, supported by $420M in cash and a recent $65.7M share sale at a premium to market. The FDA's acceptance of a cognition/behavior endpoint for EMPEROR reduces regulatory risk and differentiates zorevunersen from symptomatic competitors.
Seeking Alpha • Oct 19, 2026

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com.
Business Wire • Oct 16, 2026

Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting.
Business Wire • Oct 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Stoke Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.